Anti-hepatitis B virus efficacy of tendovir disoproxil fumarate in HIV-infected patients
Anti-hepatitis B virus efficacy of tendovir disoproxil fumarate in HIV-infected patients
复制标题
DOI：
10.1002/hep.21055
复制
发表时间：
2006-03-01
期刊：
影响因子：
13.5
通讯作者：
Piketty, C
中科院分区：
文献类型：
--
作者：
Benhamou, Y;Fleury, H;Piketty, C
富马酸替诺福韦酯（TDF）已显示出体外抗HIV和B型肝炎病毒（HBV）活性。我们回顾性评价了TDF（300 mg/d）作为抗逆转录病毒治疗的一部分，在一个大型HIV/HBV合并感染患者队列中的疗效。65例HIV/HBV合并感染患者接受TDF治疗至少6个月，TDF开始时血清HBV DNA水平高于2.3 log（10）拷贝/mL，并在TDF治疗前和治疗期间储存血清样本。血清HBV DNA测定储存的样品。中位随访期为12（Q1-Q3：8-17）个月。血清B e抗原（HBeAg）阳性54例（83.1%）。52例患者（80.0%）正在接受拉米夫定（LAM）（150 mg，每日两次），68.8%的患者在基线时记录了LAM耐药。HBeAg阳性患者血清HBV DNA较基线下降的中位数为4.56 log（10）copies/mL（Q1-Q3 = 3.33 - 5 - 55）（Q1-Q3 = 7.30-8.30 log（10）copies/mL，Q1-Q3 = 3.33-5-55）（P
Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV). We retrospectively evaluated the efficacy of TDF (300 mg/d), administered as a part of anti-retroviral therapy, in a large cohort of HIV/HBV-coinfected patients. Sixty-five HIV/HBV-coinfected patients who received TDF for at least 6 months with serum HBV DNA levels above 2.3 log(10) copies/mL at TDF initiation and who had stored serum samples before and during TDF therapy were included. Serum HBV DNA was measured on stored samples. The median follow-up period was 12 (Q1-Q3: 8-17) months. Serum hepatitis B e antigen (HBeAg) was positive in 54 patients (83.1%). Fifty-two patients (80.0%) were receiving lamivudine (LAM) (150 mg twice a day), and 68.8% had documented LAM resistance at baseline. Among HBeAg-positive patients, the median reduction from baseline (8.17; Q1-Q3 = 7.30-8.30 log(10) copies/mL) of serum HBV DNA was 4.56 log(10) copies/mL (Q1-Q3 = 3.33-5-55) (P